Pu-Yuan Xing

List of Publications by Year
in descending order

66 papers	1,117 citations	623188 14 h-index	525886 27 g-index
80 all docs	80 docs citations	80 times ranked	1523 citing authors

#	Article	IF	Citations
1	Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2017, 35, 3105-3112.	0.8	168
2	Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. , 2019, 7, 341.		126
3	Clinical characteristics and medical service utilization of lung cancer in China, 2005â€“2014: Overall design and results from a multicenter retrospective epidemiologic survey. Lung Cancer, 2019, 128, 91-100.	0.9	81
4	Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial. Clinical Cancer Research, 2019, 25, 5212-5220.	3.2	60
5	Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants. Lung Cancer, 2018, 118, 128-133.	0.9	50
6	Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2427-2433.	1.2	41
7	What are the clinical symptoms and physical signs for nonâ€small cell lung cancer before diagnosis is made? A nationâ€wide multicenter 10â€year retrospective study in China. Cancer Medicine, 2019, 8, 4055-4069.	1.3	37
8	Current management of chemotherapy-induced neutropenia in adults: key points and new challenges. Cancer Biology and Medicine, 2020, 17, 896-909.	1.4	35
9	Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib. Targeted Oncology, 2019, 14, 159-168.	1.7	33
10	Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib. Targeted Oncology, 2019, 14, 335-342.	1.7	28
11	Betulinic acid exerts potent antitumor effects on paclitaxelâ€resistant human lung carcinoma cells (H460) via G2/M phase cell cycle arrest and induction of mitochondrial apoptosis. Oncology Letters, 2018, 16, 3628-3634.	0.8	27
12	Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 603.	1.3	26
13	Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD). Translational Lung Cancer Research, 2020, 9, 2428-2439.	1.3	21
14	Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type. Annals of Hematology, 2017, 96, 1477-1483.	0.8	20
15	Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study . Cancer Management and Research, 2019, Volume 11, 9243-9251.	0.9	16
16	Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastasesâ€”a multicenter retrospective study. BMC Medicine, 2022, 20, 12.	2.3	16
17	Comparative study of clinicopathological characteristics and prognosis between combined and pure small cell lung cancer (SCLC) after surgical resection. Thoracic Cancer, 2020, 11, 2782-2792.	0.8	15
18	Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas. Lung Cancer, 2018, 122, 113-119.	0.9	14

#	Article	IF	Citations
19	Efficacy of dacomitinib in patients with <scp>EGFR</scp>â€mutated <scp>NSCLC</scp> and brain metastases. Thoracic Cancer, 2021, 12, 3407-3415.	0.8	14
20	First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC: a retrospective real-world POLISH study. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210823.	1.4	14
21	Coâ€mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer. Journal of Cellular and Molecular Medicine, 2019, 23, 6812-6821.	1.6	12
22	Epithelial circulating tumor cells with a heterogeneous phenotype are associated with metastasis in NSCLC. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1137-1146.	1.2	12
23	Circulating tumor cells (<scp>CTCs</scp>)/circulating tumor endothelial cells (<scp>CTECs</scp>) and their subtypes in small cell lung cancer: Predictors for response and prognosis. Thoracic Cancer, 2021, 12, 2749-2757.	0.8	12
24	Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma. Thoracic Cancer, 2021, 12, 2585-2593.	0.8	12
25	Sorafenib in metastatic radioactive iodine-refractory differentiated thyroid cancer: A pilot study. Molecular and Clinical Oncology, 2014, 2, 87-92.	0.4	11
26	Distinct MET Protein Localization Associated With MET Exon 14 Mutation Types in Patients With Nonâ€“small-cell Lung Cancer. Clinical Lung Cancer, 2018, 19, e391-e398.	1.1	11
27	Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations. Thoracic Cancer, 2019, 10, 1461-1468.	0.8	11
28	Real world study of regimen containing bevacizumab as firstâ€line therapy in Chinese patients with advanced nonâ€small cell lung cancer. Thoracic Cancer, 2018, 9, 805-813.	0.8	10
29	YAP1 protein expression has variant prognostic significance in small cell lung cancer (SCLC) stratified by histological subtypes. Lung Cancer, 2021, 160, 166-174.	0.9	10
30	Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALKâ€positive nonâ€small cell lung cancer: A retrospective, realâ€world study. Cancer Medicine, 2019, 8, 5823-5830.	1.3	9
31	Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China. Targeted Oncology, 2019, 14, 325-333.	1.7	9
32	Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations. Thoracic Cancer, 2021, 12, 2924-2932.	0.8	9
33	Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study. Journal of Cancer Research and Clinical Oncology, 2022, 148, 3081-3089.	1.2	9
34	Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in EGFR-Mutant Lung Adenocarcinoma. Frontiers in Oncology, 2021, 11, 591922.	1.3	8
35	ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer. Molecular Medicine, 2021, 27, 138.	1.9	8
36	Gemcitabine combined with cisplatin as adjuvant chemotherapy for nonâ€small cell lung cancer: <scp>A</scp> retrospective analysis. Thoracic Cancer, 2017, 8, 482-488.	0.8	7

#	Article	IF	Citations
37	Study protocol: A singleâ€arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with firstâ€line immunotherapy. Thoracic Cancer, 2021, 12, 2825-2828.	0.8	7
38	Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-15.	0.5	7
39	Cerebrospinal Fluid Cell-Free DNA-Based Detection of High Level of Genomic Instability Is Associated With Poor Prognosis in NSCLC Patients With Leptomeningeal Metastases. Frontiers in Oncology, 2022, 12, 664420.	1.3	7
40	Clinicopathological features and prognostic analysis of 247 small cell lung cancer with limited-stage after surgery. Human Pathology, 2021, 108, 84-92.	1.1	6
41	Clinicopathological features and prognostic implications of <scp>ASCL1</scp> expression in surgically resected small cell lung cancer. Thoracic Cancer, 2021, 12, 40-47.	0.8	6
42	EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes. Frontiers in Oncology, 2021, 11, 713483.	1.3	6
43	The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China. Oncotarget, 2017, 8, 87442-87454.	0.8	6
44	Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 349-356.	0.7	5
45	Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 481-488.	0.7	5
46	Apatinib as maintenance therapy following standard firstâ€line chemotherapy in extensive disease small cell lung cancer: A phase <scp>II</scp> singleâ€arm trial. Thoracic Cancer, 2022, 13, 557-562.	0.8	5
47	<scp>ASCL1</scp> and <scp>DLL3</scp> expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the <scp>National Cancer Center of China</scp>. Thoracic Cancer, 2022, 13, 338-345.	0.8	5
48	Efficacy and safety profile of combining programmed cell deathâ€1 (<scp>PD</scp>â€1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic nonâ€small cell lung cancer (<scp>NSCLC</scp>). Thoracic Cancer, 2021, 12, 2360-2368.	0.8	4
49	The clinical significance of RET gene fusion among Chinese patients with lung cancer. Translational Cancer Research, 2020, 9, 6455-6463.	0.4	4
50	A realâ€world study of dacomitinib in laterâ€line settings for advanced nonâ€small cell lung cancer patients harboring EGFR mutations. Cancer Medicine, 2022, 11, 1026-1036.	1.3	4
51	Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients. Cancer Management and Research, 2022, Volume 14, 863-873.	0.9	4
52	Disease monitoring of epidermal growth factor receptor (EGFR)â€mutated nonâ€smallâ€cell lung cancer patients treated with tyrosine kinase inhibitors via <scp>EGFR</scp> status in circulating tumor <scp>DNA</scp>. Thoracic Cancer, 2022, 13, 2201-2209.	0.8	4
53	Evaluation of calculating carboplatin dosage in carboplatinâ€“pemetrexed therapy as the firstâ€line therapy for Chinese patients with advanced lung adenocarcinoma. Thoracic Cancer, 2018, 9, 400-407.	0.8	3
54	Real world study of the continuation of bevacizumab beyond disease progression after firstâ€line treatment containing bevacizumab in Chinese patients with advanced nonâ€small cell lung cancer. Thoracic Cancer, 2018, 9, 1716-1724.	0.8	3

#	Article	IF	Citations
55	Clinical outcome, longâ€term survival and tolerability of sequential therapy of firstâ€line crizotinib followed by alectinib in advanced ALK + NSCLC : A multicenter retrospective analysis in China. Thoracic Cancer, 2021, , .	0.8	3
56	Evaluating stress, satisfaction and the associated influencing factors of participants in cancer clinical trials: a cross-sectional study in China. BMJ Open, 2019, 9, e028589.	0.8	1
57	Favorable predictors for survival in advanced ALK â€positive nonâ€small cell lung cancer patients beyond crizotinib resistance. Thoracic Cancer, 2019, 10, 1096-1102.	0.8	1
58	Concurrent chemotherapy and firstâ€generation epidermal growth factor receptor (EGFR)â€tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as firstâ€line treatment in advanced lung adenocarcinoma harboring an EGFR mutation. Thoracic Cancer, 2021, 12, 2233-2240.	0.8	1
59	Clinical activity and safety profile of dacomitinib in advanced epidermal growth factor receptor-positive non-small cell lung cancer patients with brain metastases.. Journal of Clinical Oncology, 2020, 38, e21656-e21656.	0.8	1
60	A real-world survival of subsequent therapy in ALK positive non-small cell lung cancer (NSCLC) patients with crizotinib resistance.. Journal of Clinical Oncology, 2018, 36, e21093-e21093.	0.8	1
61	Clinical significance of ALDH1A1 expression and its association with E-cadherin and N-cadherin in resected large cell neuroendocrine carcinoma. Translational Oncology, 2022, 19, 101379.	1.7	1
62	Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: a network meta-analysis. BMC Cancer, 2022, 22, 514.	1.1	1
63	Changes and Influential Factors of Chemotherapy Usage for Non-Small Cell Lung Cancer Patients in China: A Multicenter 10-Year (2005â€“2014) Retrospective Study . Cancer Management and Research, 2020, Volume 12, 6033-6044.	0.9	0
64	Identification of predictive biomarker for immunotherapy by associating with CD8+T cell Infiltration in lung adenocarcinoma.. Journal of Clinical Oncology, 2021, 39, e21177-e21177.	0.8	0
65	Survival of crizotinib continuation plus brain radiotherapy among ALK positive non-small cell lung cancer (NSCLC) patients with brain metastases during crizotinib treatment.. Journal of Clinical Oncology, 2018, 36, e21142-e21142.	0.8	0
66	Transcriptional analysis of small cell lung cancer transformation in epidermal growth factor receptor mutated lung adenocarcinomas.. Journal of Clinical Oncology, 2022, 40, e21100-e21100.	0.8	0